GW-1100GPR40 antagonist CAS# 306974-70-9 |
- TAK-875
Catalog No.:BCC3702
CAS No.:1000413-72-8
- GSK1292263
Catalog No.:BCC3786
CAS No.:1032823-75-8
- GPR40 Activator 1
Catalog No.:BCC4125
CAS No.:1309435-60-6
- TUG-770
Catalog No.:BCC2018
CAS No.:1402601-82-4
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 306974-70-9 | SDF | Download SDF |
PubChem ID | 11692123 | Appearance | Powder |
Formula | C27H25FN4O4S | M.Wt | 520.59 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (96.05 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | ethyl 4-[5-[(2-ethoxypyrimidin-5-yl)methyl]-2-[(4-fluorophenyl)methylsulfanyl]-4-oxopyrimidin-1-yl]benzoate | ||
SMILES | CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC | ||
Standard InChIKey | PTPNCCWOTBBVJR-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C27H25FN4O4S/c1-3-35-25(34)20-7-11-23(12-8-20)32-16-21(13-19-14-29-26(30-15-19)36-4-2)24(33)31-27(32)37-17-18-5-9-22(28)10-6-18/h5-12,14-16H,3-4,13,17H2,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | GW-1100 is a selective GPR40 antagonist with a pIC50 of 6.9. GW1100 acts as a GPR40 inverse agonist.In Vitro:GW-1100 (GW1100) dose dependently inhibits GPR40-mediated Ca2+ elevations stimulated by GW9508 and linoleic acid (pIC50 values of 5.99±0.03 and 5.99±0.06, respectively). GW-1100 at a concentration of 1 μM produces a significant rightward shift in the concentration-response curve to GW9508 (pEC50=7.17±0.08 in the absence and pEC50=6.79±0.09 in the presence of 1 μM GW-1100; P<0.05; n=3). At concentrations of GW-1100 of 3 μM and higher a significant decrease in the maximal response is observed with a continuing rightward shift in the pEC50 response[2]. GW-1100 (GW1100) reduces FFAR1 ligand-induced intracellular calcium in CHO-K1/bFFAR1 cells and neutrophils. CHO-K1/bFFAR1 cells are incubated for 15 min with 10 μM GW1100 or vehicle (0.1% DMSO) and then stimulated with vehicle, oleic acid, linoleic acid or GW9508. GW-1100 significantly reduces the increase in intracellular calcium induced by 300 μM oleic acid (AUC(60-150 s), p<0.05), 100 μM linoleic acid (AUC(60-150 s), p<0.05) and 10 μM GW9508 (AUC(60-150 s), p<0.05)[3].In Vivo:The intracerebroventricular injection of DHA (50 µg) and GW9508 (1.0 µg), a GPR40-selective agonist, significantly reduces mechanical allodynia and thermal hyperalgesia at day 7, but not at day 1, after CFA injection. These effects are inhibited by intracerebroventricular pretreatment with GW-1100 (10 µg), a GPR40 antagonist[4]. References: |
GW-1100 Dilution Calculator
GW-1100 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9209 mL | 9.6045 mL | 19.209 mL | 38.4179 mL | 48.0224 mL |
5 mM | 0.3842 mL | 1.9209 mL | 3.8418 mL | 7.6836 mL | 9.6045 mL |
10 mM | 0.1921 mL | 0.9604 mL | 1.9209 mL | 3.8418 mL | 4.8022 mL |
50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.7684 mL | 0.9604 mL |
100 mM | 0.0192 mL | 0.096 mL | 0.1921 mL | 0.3842 mL | 0.4802 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GW1100 is a selective GPR40 antagonist. It dose dependently inhibited GPR40-mediated Ca2+ elevations stimulated by GW9508 and linoleic acid with pIC50 values of 5.9970.03 and 5.9970.06, respectively 1.
GW1100 inhibited the Ca2+ elevations stimulated by GW9508 mediated by GPR40, but not those mediated via GPR120 by either GW9508 or linoleic acid, demonstrating that GW1100 was a selective antagonist of the GPR40 receptor. GW1100 reversed the effects of GW9508 on insulin secretion, but only partially attenuated linoleic acid-stimulated insulin secretion 1. Ishikawa cells were treated with a GPR40 antagonist, GW1100, in conjunction with GW9508. GW1100 had no effect on the stimulation of cell proliferation, suggesting all pro-proliferative effects of GW9508 are mediated through GPR120 2.
References:
1. Briscoe CP, Peat AJ, McKeown SC et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006 Jul;148(5):619-28.
2. http://www.aups.org.au/Proceedings/41/44P
- IBC 293
Catalog No.:BCC7376
CAS No.:306935-41-1
- TCID
Catalog No.:BCC4449
CAS No.:30675-13-9
- 5-Methoxy-7-hydroxycoumarin
Catalog No.:BCN3538
CAS No.:3067-10-5
- Cycloolivil
Catalog No.:BCN4081
CAS No.:3064-05-9
- (20S)-Protopanaxdiol
Catalog No.:BCN1254
CAS No.:30636-90-9
- AVE 0991 sodium salt
Catalog No.:BCC4222
CAS No.:306288-04-0
- 2,2-Diphenylglycine
Catalog No.:BCC8496
CAS No.:3060-50-2
- Spermine tetrahydrochloride
Catalog No.:BCC6864
CAS No.:306-67-2
- Homovanillic acid
Catalog No.:BCN1253
CAS No.:306-08-1
- SC 79
Catalog No.:BCC6246
CAS No.:305834-79-1
- 3,9-Bis(2-cyanoethyl)-2,4,8,10-tetraoxaspiro[5.5]undecane
Catalog No.:BCC8599
CAS No.:3058-04-6
- H-Asp(OtBu)-OH
Catalog No.:BCC2891
CAS No.:3057-74-7
- CL 82198 hydrochloride
Catalog No.:BCC2372
CAS No.:307002-71-7
- WAY 170523
Catalog No.:BCC2380
CAS No.:307002-73-9
- 1,4-Bis[2-(4-methyl-5-phenyloxazolyl)]benzene
Catalog No.:BCC8425
CAS No.:3073-87-8
- Troxipide
Catalog No.:BCC4744
CAS No.:30751-05-4
- CFTRinh-172
Catalog No.:BCC4419
CAS No.:307510-92-5
- SMER 28
Catalog No.:BCC7908
CAS No.:307538-42-7
- STF 083010
Catalog No.:BCC6209
CAS No.:307543-71-1
- Crosemperine
Catalog No.:BCN2074
CAS No.:30785-56-9
- [Des-octanoyl]-Ghrelin (rat)
Catalog No.:BCC5953
CAS No.:307950-60-3
- beta-Anhydrouzarigenin
Catalog No.:BCN5222
CAS No.:3080-20-4
- L-Theanine
Catalog No.:BCN2571
CAS No.:3081-61-6
- AEBSF.HCl
Catalog No.:BCC1219
CAS No.:30827-99-7